Maxim Pharmaceuticals, Inc. (MAXM) Announces Initiation Of New Apoptosis Screening Campaign And Publication Of Manuscript In Journal Of Medicinal Chemistry
10/19/2005 5:13:16 PM
SAN DIEGO--(BUSINESS WIRE)--April 12, 2005--Maxim Pharmaceuticals, Inc. (NASDAQ:MAXM)(SSE:MAXM) announced today the initiation of a new screening campaign using approximately 60,000 compounds recently acquired for its compound library to identify potential new anticancer agents and novel molecular targets for inducing apoptosis in cancer cells. As with other compounds in Maxim's library, the new compounds are not subject to any financial or legal restrictions aside from the cost of purchase. By synthesis of analogs of the initial hit to improve potency and other pharmacologic properties, Maxim establishes a broad and proprietary intellectual property position on any potential lead compound candidate. The Company has already identified four novel potential cancer drug candidates from prior screening activities. The most advanced of the lead compounds has entered the clinical development through a partnership with Myriad Genetics, and the others are expected to move into the clinic over the next 12 to 18 months, either independently or through additional collaborations.
comments powered by